Back

Secretome-Mediated Antimicrobial and Immunomodulatory Activity of Lactobacillus johnsonii Against Multidrug-Resistant Enteroaggregative Escherichia coli

VASAMSETTI, S. M.; G L, M.; Khaderbad, Y.; Gupta, A.; Morampudi, V.

2026-04-03 microbiology
10.64898/2026.04.02.716048 bioRxiv
Show abstract

Enteroaggregative Escherichia coli (EAEC) is a leading cause of persistent diarrhea in children in low- and middle-income countries, and the emergence of multidrug-resistant (MDR) strains necessitates non-antibiotic therapeutic strategies. This study evaluates Lactobacillus johnsonii, previously characterized by our group, as a probiotic candidate against a clinically confirmed MDR EAEC isolate resistant to ampicillin, ciprofloxacin, azithromycin, amoxicillin, and gentamicin. L. johnsonii demonstrated robust gastrointestinal resilience, high cell surface hydrophobicity, phenol tolerance, and rapid autoaggregation reaching 80.4 {+/-} 2.3% by 4 hours, collectively supporting mucosal colonization potential. In antimicrobial assays, L. johnsonii produced zones of inhibition against MDR EAEC substantially exceeding those of gentamicin, reduced viable biofilm-associated EAEC by over 80%, and displaced pre-adhered EAEC from HCT-116 intestinal epithelial cells in a time-dependent manner. L. johnsonii also attenuated MDR EAEC-induced gas production and reduced nitric oxide levels by 67.7% in infected RAW 264.7 macrophages, suggesting immunomodulatory activity. Nutrient competition did not appear to contribute to EAEC suppression under tested conditions, indicating inhibition is predominantly secretome-dependent. Fractionation of the L. johnsonii cell-free supernatant by fast protein liquid chromatography yielded five fractions below 75 kDa; fractions S5 and S6 exhibited sustained bactericidal activity at 6 hours. Gram staining confirmed that both fractions reduced viable EAEC cell numbers, with S6 producing a greater reduction than S5, indicating quantitatively distinct bactericidal potencies. These in vitro findings support the potential of L. johnsonii as a biotherapeutic candidate for antibiotic-resistant enteric infections. In vivo validation and chemical characterization of active fractions remain important next steps.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Antibiotics
32 papers in training set
Top 0.1%
12.5%
2
Frontiers in Microbiology
375 papers in training set
Top 0.5%
10.1%
3
Gut Microbes
70 papers in training set
Top 0.1%
8.4%
4
Antimicrobial Agents and Chemotherapy
167 papers in training set
Top 0.3%
8.4%
5
mBio
750 papers in training set
Top 2%
7.2%
6
Microbiology Spectrum
435 papers in training set
Top 0.2%
6.4%
50% of probability mass above
7
mSphere
281 papers in training set
Top 0.6%
6.3%
8
ACS Infectious Diseases
74 papers in training set
Top 0.3%
3.6%
9
Nature Communications
4913 papers in training set
Top 40%
3.6%
10
Frontiers in Cellular and Infection Microbiology
98 papers in training set
Top 2%
2.1%
11
Microbial Biotechnology
29 papers in training set
Top 0.3%
2.1%
12
npj Biofilms and Microbiomes
56 papers in training set
Top 0.9%
1.9%
13
Applied and Environmental Microbiology
301 papers in training set
Top 2%
1.8%
14
Microbiology
57 papers in training set
Top 0.6%
1.7%
15
Scientific Reports
3102 papers in training set
Top 58%
1.7%
16
Food & Function
12 papers in training set
Top 0.3%
1.7%
17
mSystems
361 papers in training set
Top 5%
1.7%
18
The Journal of Infectious Diseases
182 papers in training set
Top 3%
1.7%
19
Microorganisms
101 papers in training set
Top 1%
1.2%
20
Infection and Immunity
103 papers in training set
Top 0.5%
1.1%
21
Microbiome
139 papers in training set
Top 2%
0.9%
22
eLife
5422 papers in training set
Top 52%
0.9%
23
Nutrients
64 papers in training set
Top 2%
0.9%
24
PLOS ONE
4510 papers in training set
Top 68%
0.7%
25
International Journal of Molecular Sciences
453 papers in training set
Top 17%
0.7%
26
Advanced Science
249 papers in training set
Top 22%
0.6%